[Aspects of Bcl-2 proto-oncogene expression in dysplastic and malignant lesions of the uterine cervix].
We studied Bcl-2 proto-oncogene expression in dysplastic and malignant lesions of the uterine cervix and looked for a relation between its incidence and tumor histopathologic type and tumor differentiation grade. We used immunohistochemical reaction with a Bcl-2 specific monoclonal antibody in order to identify this protein in 40 patients' biopsies. We noticed a Bcl-2 nuclear immunoreaction in high differentiated squamous carcinomas, whereas a positive cytoplasmic reaction of a granular pattern was registered in low differentiated types. Distribution and intensity of Bcl-2 reaction final product was correlated with tumor differentiation grade in 29 of all studied cases (72.5%). Immunostaining technique may be an important adjuvant factor for a more accurate prognosis.
Borţun
F
F
Spitalul Judeţean Reşiţa.
Chiovschi
S
S
Moldovan
Mihaela
M
D002294:Carcinoma, Squamous Cell / Q000737:chemistry* / Q000473:pathology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D011379:Prognosis; D000090063:Proto-Oncogene Mas; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000032:analysis* / Q000276:immunology; D002578:Uterine Cervical Dysplasia / Q000737:chemistry* / Q000473:pathology; D002583:Uterine Cervical Neoplasms / Q000737:chemistry* / Q000473:pathology
C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D019253:Proto-Oncogene Proteins c-bcl-2